Abstract
Neuronal proteostasis is a highly regulated and crucial component of neural function. Unlike other tissues and organ, cell loss due to damage and dysfunctional signaling mechanisms is not an option for the brain. Neurons are thusly dependent on the collective cellular machinery of the molecular chaperones. Hsp70, a molecular chaperone which hydrolyzes ATP to fold proteins into a functional state, has been implicated as both a driver of disease pathogenesis and a therapeutic target for the activities and associations identified in several neurodegenerative diseases. Through interaction studies, genetic models, and small molecule therapeutics which serve as chemical tools, we have gained a greater understanding and appreciation for the role of Hsp70 in several neurodegenerative diseases. This chapter will discuss the studies and tools which elucidated the role of Hsp70 family members in neurodegenerative disorders and will offer perspective into therapeutic interventions which may prove beneficial for treating these diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- α-syn:
-
α-synuclein
- Aß:
-
Amyloid beta
- AD:
-
Alzheimer’s disease
- ALS:
-
Amyotrophic lateral sclerosis
- AMPA:
-
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- BAG-1:
-
Bcl2-associated athanogene-1
- CHIP:
-
c-terminus of Hsc70 interacting protein
- CME:
-
Clatherin-mediated endocytosis
- fALS:
-
Familial Amyotrophic lateral sclerosis
- GA:
-
Geldanamycin
- HD:
-
Huntington’s disease
- Hsc:
-
Heat shock cognate
- Hsp:
-
Heat shock protein
- LRRK2:
-
Leucine-rich repeat kinase 2
- MAPT, tau:
-
Microtubule associating protein tau
- PCR:
-
Polymerase chain reaction
- PD:
-
Parkinson’s disease
- polyQ:
-
Polyglutamine-expansions
- SCA:
-
Spinocerebellar ataxia
- SNpc:
-
Substantia nigra pars compacta
- SOD1:
-
Superoxide dismutase 1
- TDP-43:
-
TAR DNA binding protein 43
- UPS:
-
Ubiquitin-proteasome system
References
Abisambra, J., Jinwal, U. K., Miyata, Y., Rogers, J., Blair, L., Li, X., Seguin, S. P., Wang, L., Jin, Y., Bacon, J., et al. (2013). Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biological Psychiatry, 74, 367–374.
Al-Ramahi, I., Lam, Y. C., Chen, H. K., de Gouyon, B., Zhang, M., Perez, A. M., Branco, J., de Haro, M., Patterson, C., Zoghbi, H. Y., et al. (2006). CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. The Journal of Biological Chemistry, 281(36), 26714–26724.
Aprile, F. A., Sormanni, P., & Vendruscolo, M. (2015). A rational design strategy for the selective activity enhancement of a molecular chaperone toward a target substrate. Biochemistry, 54, 5103–5112.
Aprile, F. A., Kallstig, E., Limorenko, G., Vendruscolo, M., Ron, D., & Hansen, C. (2017). The molecular chaperones DNAJB6 and Hsp70 cooperate to suppress alpha-synuclein aggregation. Scientific Reports, 7, 9039.
Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M., & Bonini, N. M. (2002). Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science, 295, 865–868.
Batulan, Z., Taylor, D. M., Aarons, R. J., Minotti, S., Doroudchi, M. M., Nalbantoglu, J., & Durham, H. D. (2006). Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiology of Disease, 24, 213–225.
Beere, H. M., Wolf, B. B., Cain, K., Mosser, D. D., Mahboubi, A., Kuwana, T., Tailor, P., Morimoto, R. I., Cohen, G. M., & Green, D. R. (2000). Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nature Cell Biology, 2, 469–475.
Boluda, S., Iba, M., Zhang, B., Raible, K. M., Lee, V. M., & Trojanowski, J. Q. (2015). Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains. Acta Neuropathologica, 129, 221–237.
Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., et al. (1997). ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron, 18, 327–338.
Choi, J. S., Cho, S., Park, S. G., Park, B. C., & Lee, D. H. (2004). Co-chaperone CHIP associates with mutant Cu/Zn-superoxide dismutase proteins linked to familial amyotrophic lateral sclerosis and promotes their degradation by proteasomes. Biochemical and Biophysical Research Communications, 321, 574–583.
Cummings, C. J., Mancini, M. A., Antalffy, B., DeFranco, D. B., Orr, H. T., & Zoghbi, H. Y. (1998). Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genetics, 19, 148–154.
Cummings, C. J., Sun, Y., Opal, P., Antalffy, B., Mestril, R., Orr, H. T., Dillmann, W. H., & Zoghbi, H. Y. (2001). Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Human Molecular Genetics, 10, 1511–1518.
Dayalu, P., & Albin, R. L. (2015). Huntington disease: Pathogenesis and treatment. Neurologic Clinics, 33, 101–114.
Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007). The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. The Journal of Clinical Investigation, 117, 648–658.
Dickey, C. A., Koren, J., Zhang, Y. J., Xu, Y. F., Jinwal, U. K., Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., et al. (2008). Akt and CHIP coregulate tau degradation through coordinated interactions. Proceedings of the National Academy of Sciences of the United States of America, 105, 3622–3627.
Dou, F., Netzer, W. J., Tanemura, K., Li, F., Hartl, F. U., Takashima, A., Gouras, G. K., Greengard, P., & Xu, H. (2003). Chaperones increase association of tau protein with microtubules. Proceedings of the National Academy of Sciences of the United States of America, 100, 721–726.
Durham, H. D., Roy, J., Dong, L., & Figlewicz, D. A. (1997). Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. Journal of Neuropathology and Experimental Neurology, 56, 523–530.
Durr, A., Gargiulo, M., & Feingold, J. (2012). The presymptomatic phase of Huntington disease. Revue Neurologique (Paris), 168, 806–808.
Elliott, E., Tsvetkov, P., & Ginzburg, I. (2007). BAG-1 associates with Hsc70.Tau complex and regulates the proteasomal degradation of Tau protein. The Journal of Biological Chemistry, 282, 37276–37284.
Evans, C. G., Jinwal, U. K., Makley, L. N., Dickey, C. A., & Gestwicki, J. E. (2011). Identification of dihydropyridines that reduce cellular tau levels. Chemical Communication (Cambridge), 47, 529–531.
Falsone, S. F., Kungl, A. J., Rek, A., Cappai, R., & Zangger, K. (2009). The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. The Journal of Biological Chemistry, 284, 31190–31199.
Flower, T. R., Chesnokova, L. S., Froelich, C. A., Dixon, C., & Witt, S. N. (2005). Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson’s disease. Journal of Molecular Biology, 351, 1081–1100.
Fontaine, S. N., Zheng, D., Sabbagh, J. J., Martin, M. D., Chaput, D., Darling, A., Trotter, J. H., Stothert, A. R., Nordhues, B. A., Lussier, A., et al. (2016). DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins. The EMBO Journal, 35, 1537–1549.
Fukuzono, T., Pastuhov, S. I., Fukushima, O., Li, C., Hattori, A., Iemura, S., Natsume, T., Shibuya, H., Hanafusa, H., Matsumoto, K., et al. (2016). Chaperone complex BAG2-HSC70 regulates localization of Caenorhabditis elegans leucine-rich repeat kinase LRK-1 to the Golgi. Genes to Cells, 21, 311–324.
Gao, X., Carroni, M., Nussbaum-Krammer, C., Mogk, A., Nillegoda, N. B., Szlachcic, A., Guilbride, D. L., Saibil, H. R., Mayer, M. P., & Bukau, B. (2015). Human Hsp70 disaggregase reverses Parkinson’s-linked alpha-synuclein amyloid fibrils. Molecular Cell, 59, 781–793.
Guo, J. L., Narasimhan, S., Changolkar, L., He, Z., Stieber, A., Zhang, B., Gathagan, R. J., Iba, M., McBride, J. D., Trojanowski, J. Q., et al. (2016). Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice. The Journal of Experimental Medicine, 213, 2635–2654.
Iba, M., McBride, J. D., Guo, J. L., Zhang, B., Trojanowski, J. Q., & Lee, V. M. (2015). Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC’s afferent and efferent connections. Acta Neuropathologica, 130, 349–362.
Ishigaki, S., Niwa, J., Yamada, S., Takahashi, M., Ito, T., Sone, J., Doyu, M., Urano, F., & Sobue, G. (2007). Dorfin-CHIP chimeric proteins potently ubiquitylate and degrade familial ALS-related mutant SOD1 proteins and reduce their cellular toxicity. Neurobiology of Disease, 25, 331–341.
Jana, N. R., Tanaka, M., Wang, G., & Nukina, N. (2000). Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Human Molecular Genetics, 9, 2009–2018.
Jana, N. R., Dikshit, P., Goswami, A., Kotliarova, S., Murata, S., Tanaka, K., & Nukina, N. (2005). Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. The Journal of Biological Chemistry, 280, 11635–11640.
Jankovic, J. (2008). Parkinson’s disease: Clinical features and diagnosis. Journal of Neurology, Neurosurgery, and Psychiatry, 79, 368–376.
Jinwal, U. K., Miyata, Y., Koren, J., 3rd, Jones, J. R., Trotter, J. H., Chang, L., O’Leary, J., Morgan, D., Lee, D. C., Shults, C. L., et al. (2009). Chemical manipulation of hsp70 ATPase activity regulates tau stability. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 29, 12079–12088.
Jinwal, U. K., O’Leary, J. C., 3rd, Borysov, S. I., Jones, J. R., Li, Q., Koren, J., 3rd, Abisambra, J. F., Vestal, G. D., Lawson, L. Y., Johnson, A. G., et al. (2010). Hsc70 rapidly engages tau after microtubule destabilization. The Journal of Biological Chemistry, 285, 16798–16805.
Kalmar, B., Novoselov, S., Gray, A., Cheetham, M. E., Margulis, B., & Greensmith, L. (2008). Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. Journal of Neurochemistry, 107, 339–350.
Kalmar, B., Edet-Amana, E., & Greensmith, L. (2012). Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis: Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 13, 378–392.
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003). A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 425, 407–410.
Kelly, E. B. (2013). Encyclopedia of human genetics and disease (Vol. 1). Santa Barbara: ABC-CLIO.
Kieran, D., Kalmar, B., Dick, J. R., Riddoch-Contreras, J., Burnstock, G., & Greensmith, L. (2004). Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nature Medicine, 10, 402–405.
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011). Amyotrophic lateral sclerosis. Lancet, 377, 942–955.
Klucken, J., Shin, Y., Hyman, B. T., & McLean, P. J. (2004). A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochemical and Biophysical Research Communications, 325, 367–373.
Koren, J., 3rd, Jinwal, U. K., Jin, Y., O’Leary, J., Jones, J. R., Johnson, A. G., Blair, L. J., Abisambra, J. F., Chang, L., Miyata, Y., et al. (2010). Facilitating Akt clearance via manipulation of Hsp70 activity and levels. The Journal of Biological Chemistry, 285, 2498–2505.
Koyama, S., Arawaka, S., Chang-Hong, R., Wada, M., Kawanami, T., Kurita, K., Kato, M., Nagai, M., Aoki, M., Itoyama, Y., et al. (2006). Alteration of familial ALS-linked mutant SOD1 solubility with disease progression: Its modulation by the proteasome and Hsp70. Biochemical and Biophysical Research Communications, 343, 719–730.
Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., & Lansbury, P. T., Jr. (2002). Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. Journal of Molecular Biology, 322, 1089–1102.
Lichtenberg, M., Mansilla, A., Zecchini, V. R., Fleming, A., & Rubinsztein, D. C. (2011). The Parkinson’s disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death & Disease, 2, e196.
Liu, J., Shinobu, L. A., Ward, C. M., Young, D., & Cleveland, D. W. (2005). Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis. Journal of Neurochemistry, 93, 875–882.
Lotz, G. P., Legleiter, J., Aron, R., Mitchell, E. J., Huang, S. Y., Ng, C., Glabe, C., Thompson, L. M., & Muchowski, P. J. (2010). Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. The Journal of Biological Chemistry, 285, 38183–38193.
Luk, K. C., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2008). Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. Biochemistry, 47, 12614–12625.
McLean, P. J., Klucken, J., Shin, Y., & Hyman, B. T. (2004). Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochemical and Biophysical Research Communications, 321, 665–669.
Monsellier, E., Redeker, V., Ruiz-Arlandis, G., Bousset, L., & Melki, R. (2015). Molecular interaction between the chaperone Hsc70 and the N-terminal flank of huntingtin exon 1 modulates aggregation. The Journal of Biological Chemistry, 290, 2560–2576.
Muchowski, P. J., Schaffar, G., Sittler, A., Wanker, E. E., Hayer-Hartl, M. K., & Hartl, F. U. (2000). Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proceedings of the National Academy of Sciences of the United States of America, 97, 7841–7846.
O’Leary, J. C., 3rd, Li, Q., Marinec, P., Blair, L. J., Congdon, E. E., Johnson, A. G., Jinwal, U. K., Koren, J., 3rd, Jones, J. R., Kraft, C., et al. (2010). Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Molecular Neurodegeneration, 5, 45.
Opazo, F., Krenz, A., Heermann, S., Schulz, J. B., & Falkenburger, B. H. (2008). Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. Journal of Neurochemistry, 106, 529–540.
Orr, H. T. (2012). Cell biology of spinocerebellar ataxia. The Journal of Cell Biology, 197, 167–177.
Park, S. H., Kukushkin, Y., Gupta, R., Chen, T., Konagai, A., Hipp, M. S., Hayer-Hartl, M., & Hartl, F. U. (2013). PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone. Cell, 154, 134–145.
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O’Regan, J. P., Deng, H. X., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362, 59–62.
Roy, J., Minotti, S., Dong, L., Figlewicz, D. A., & Durham, H. D. (1998). Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 18, 9673–9684.
Shimura, H., Schwartz, D., Gygi, S. P., & Kosik, K. S. (2004). CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. The Journal of Biological Chemistry, 279, 4869–4876.
St Martin, J. L., Klucken, J., Outeiro, T. F., Nguyen, P., Keller-McGandy, C., Cantuti-Castelvetri, I., Grammatopoulos, T. N., Standaert, D. G., Hyman, B. T., & McLean, P. J. (2007). Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. Journal of Neurochemistry, 100, 1449–1457.
Tantucci, M., Mariucci, G., Taha, E., Spaccatini, C., Tozzi, A., Luchetti, E., Calabresi, P., & Ambrosini, M. V. (2009). Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment. Neuroscience, 163, 735–740.
Tetzlaff, J. E., Putcha, P., Outeiro, T. F., Ivanov, A., Berezovska, O., Hyman, B. T., & McLean, P. J. (2008). CHIP targets toxic alpha-synuclein oligomers for degradation. The Journal of Biological Chemistry, 283, 17962–17968.
Thompson, A. D., Scaglione, K. M., Prensner, J., Gillies, A. T., Chinnaiyan, A., Paulson, H. L., Jinwal, U. K., Dickey, C. A., & Gestwicki, J. E. (2012). Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chemical Biology, 7(10), 1677–1686.
Voss, K., Combs, B., Patterson, K. R., Binder, L. I., & Gamblin, T. C. (2012). Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry, 51, 888–898.
Warrick, J. M., Chan, H. Y., Gray-Board, G. L., Chai, Y., Paulson, H. L., & Bonini, N. M. (1999). Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nature Genetics, 23, 425–428.
Watanabe, M., Dykes-Hoberg, M., Culotta, V. C., Price, D. L., Wong, P. C., & Rothstein, J. D. (2001). Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiology of Disease, 8, 933–941.
Williams, A. J., Knutson, T. M., Colomer Gould, V. F., & Paulson, H. L. (2009). In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiology of Disease, 33, 342–353.
Witt, S. N. (2010). Hsp70 molecular chaperones and Parkinson’s disease. Biopolymers, 93, 218–228.
Yoo, B. C., Seidl, R., Cairns, N., & Lubec, G. (1999). Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer’s disease. Journal of Neural Transmission. Supplementum, 57, 315–322.
Yu, A., Shibata, Y., Shah, B., Calamini, B., Lo, D. C., & Morimoto, R. I. (2014). Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition. Proceedings of the National Academy of Sciences of the United States of America, 111, E1481–E1490.
Zarei, S., Carr, K., Reiley, L., Diaz, K., Guerra, O., Altamirano, P. F., Pagani, W., Lodin, D., Orozco, G., & Chinea, A. (2015). A comprehensive review of amyotrophic lateral sclerosis. Surgical Neurology International, 6, 171.
Zetterstrom, P., Graffmo, K. S., Andersen, P. M., Brannstrom, T., & Marklund, S. L. (2011). Proteins that bind to misfolded mutant superoxide dismutase-1 in spinal cords from transgenic amyotrophic lateral sclerosis (ALS) model mice. The Journal of Biological Chemistry, 286, 20130–20136.
Acknowledgements
This book chapter is dedicated to the life and memory of Dr. Chad A. Dickey. We apologize to the many authors who have contributed to our understanding of the molecular chaperone and neurodegenerative disease fields, and whose work we have failed to discuss or cite.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Sun, Z., Blackburn, R.J., Blair, L.J., Koren, J. (2018). Hsp70-Family Proteins and Neurodegenerative Diseases. In: Asea, A., Kaur, P. (eds) HSP70 in Human Diseases and Disorders. Heat Shock Proteins, vol 14. Springer, Cham. https://doi.org/10.1007/978-3-319-89551-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-89551-2_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-89550-5
Online ISBN: 978-3-319-89551-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)